找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: ;

[复制链接]
楼主: Enclosure
发表于 2025-3-30 10:28:23 | 显示全部楼层
Novel Antibiotics in Urologye last 10 years are considered including one new siderophore cephalosporin, two new carbapenems, three cephalosporin/beta-lactamase inhibitor and two carbapenem/beta-lactamase inhibitor combinations, one novel aminoglycoside, two new fluoroquinolones, a new tetracycline, and the revival of the parenteral fosfomycin disodium.
发表于 2025-3-30 12:39:09 | 显示全部楼层
发表于 2025-3-30 17:16:56 | 显示全部楼层
发表于 2025-3-31 00:43:58 | 显示全部楼层
发表于 2025-3-31 04:09:05 | 显示全部楼层
发表于 2025-3-31 06:26:02 | 显示全部楼层
The Treatment of Urinary Tract Infections Caused by ESBL-Producing Gram-Negative Bacteria, Vancomyciatients with urinary tract infections (UTI) caused by ESBL, VRE, and MDR bacteria..This chapter aims to comprehensively discuss current antibacterial treatment options for uncomplicated and complicated UTI caused by multiresistant microorganisms and to provide an overview of currently available as well as upcoming therapeutic options.
发表于 2025-3-31 10:28:27 | 显示全部楼层
Bacteriophage Therapy for Urinary Tract Infections., we delve into the specific clinical applications of phages for treating urinary tract infections (UTIs) in patients and provide our perspective on the future of phage therapy in combating urological infections.
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-28 03:48
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表